2023 / 05

Next Paper
DOI: 10.24075/brsmu.2023.039

ORIGINAL RESEARCH

Gene geography of pharmacogenetically significant CYP2C19 cytochrome superfamily DNA markers in the populations of Russia and neighboring countries

Balanovska EV1, Abdulaev ShP2, Gorin IO1, Belov RO1, Mukatdarova EA1, Pylev VYu1,3
About authors

1 Research Centre for Medical Genetics, Moscow, Russia

2 Russian Medical Academy of Continuous Professional Education, Moscow, Russia

3 Biobank of North Eurasia, Moscow, Russia

Correspondence should be addressed: Elena V. Balanovska
Moskvorechye, 1, 115522, Moscow, Russia; ur.liam@aksvonalab

About paper

Funding: the study was supported by the Russian Science Foundation grant № 21-14-00363 (bioinformatics, statistical and cartographic analysis), State Assignment of the Ministry of Science and Higher Education of the Russian Federation for the Research Centre for Medical Genetics (genealogical analysis, interpretation of the results).

Acknowledgements: the authors would like to thank all sample donors, who took part in the study, and Biobank of North Eurasia for access to DNA collections.

Author contribution: Balanovska EV — data analysis, manuscript writing, research management; Abdulaev ShP — discriptions of pharmacogenetic markers; Gorin IO — bioinformatics analysis; Belov RO — manuscript formatting; Mukatdarova EA — working with genealogical database; Pylev VYu — statistical analysis, cartographic analysis.

Compliance with ethical standards: the study was approved by the Ethics Commitee of the Research Centre for Medical Genetics (protocol № 1 of 29 June 2020); all subjects submitted the informed consent to study participation.

Received: 2023-09-18 Accepted: 2023-10-18 Published online: 2023-10-31
|
  1. Mini E, Nobili S. Pharmacogenetics: implementing personalized medicine. Clinical cases in mineral and bone metabolism. 2009; 6 (1):17.
  2. Samani NJ, Tomaszewski M, Schunkert H. The personal genome — the future of personalised medicine? The Lancet. 2010; 375 (9725): 1497–8.
  3. Collins FS, Varmus H. A new initiative on precision medicine. New England journal of medicine. 2015; 372 (9): 793–5.
  4. Sinitsina II, Boyarko AV, Temirbulatov II, Sychev DA, Akmalova KA, Sozaeva ZA, et al. CYP2C9 gene polymorphisms influence on antihypertensive effectiveness and hypouricemic effect of losartan among patients with arterial hypertension: an observational study. Drug Metabolism and Personalized Therapy. 2022; 38 (2): 163–8.
  5. Lee CR, Luzum JA, Sangkuhl K, Gammal RS, Sabatine MS, Stein CM, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update. Clinical Pharmacology & Therapeutics. 2022; 112 (5): 959–67.
  6. Niu X, Mao L, Huang Y, Baral S, Li JY, Gao Y, et al. CYP2C19 polymorphism and clinical outcomes among patients of different races treated with clopidogrel: a systematic review and metaanalysis. Journal of Huazhong University of Science and Technology [Medical Sciences]. 2015; 35 (2): 147–56.
  7. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmöller J, Frötschl R, Köpke K, et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. European journal of clinical pharmacology. 2003; 59: 303–12.
  8. Johnson JA, Caudle KE, Gong L, Whirl–Carrillo M, Stein CM, Scott SA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics–guided warfarin dosing: 2017 update. Clinical Pharmacology & Therapeutics. 2017; 102 (3): 397–404.
  9. Pyljov VJu, Agdzhojan AT, Gorin IO, Petrushenko VS, Pocheshhova JeA, Balanovskaja EV i dr. Populjacionnyj biobank kak osnova dlja vyjavlenija prostranstvennoj izmenchivosti klinicheski znachimyh farmakogeneticheskih biomarkerov serdechno-sosudistyh zabolevanij. Kardiovaskuljarnaja terapija i profilaktika. 2022; 21 (11): 114–34. Russian.
  10. Balanovska EV, Petrushenko VS, Koshel SM, Pocheshkhova EA, Chernevskiy DK, Mirzaev KB, Abdullaev ShP, Balanovsky OP, et al. Cartographic atlas of frequency variation for 45 pharmacogenetic markers in populations of Russia and its neighbor states. Bulletin of RSMU. 2020 (6): 38–51.
  11. Balanovska EV, Gorin IO, Ponomarev GYu, Pylev VYu, Petrushenko VS, Markina NV, Mamaeva AD, Larin AK, Agdzhoyan AT et al. Footprints of interaction among Finniс-speaking, Slavic, and Turkic-speaking populations in modern gene pool and their reflection in pharmacogenetics. Bulletin of RSMU. 2022; 2: 20–9.
  12. Balanovska EV, Napolskih VV, Churakov VS, Pislegin NV, Zapiseckaja YuS, Balanovsky OP, i dr. Genofondy udmurtov i besermjan v kontekste finno-ugorskih i drugih okruzhajushhih narodov: polnogenomnye i farmakogeneticheskie dannye. Ezhegodnik finno-ugorskih issledovanij. 2022; 2: 328–46. Russian.
  13. Balanovsky O, Petrushenko V, Gorin I, Agdzhoyan A, Balanovska E, Sychev D, et al. Variation of genomic sites associated with severe Covid-19 across populations: global and national patterns. Pharmacogenomics and Personalized Medicine. 2021: 1391– 402.
  14. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015; 4 (1): s13742–015.
  15. GG-base [cited 2022 Sep 10]. Available from: https://gg-base.org/.
  16. Balanovska EV, Zhabagin MK, Agdzhoyan AT, Chuhryaeva MI, Markina NV, Asylguzhin RR, i dr. Populjacionnye biobanki: principy organizacii i perspektivy primenenija v genogeografii i personalizirovannoj medicine. Genetika. 2016; 52 (12): 1371–87. Russian.
  17. Koshel SM. Geoinformacionnye tehnologii v genogeografii. Sovremennaja geograficheskaja kartografija. 2012; c. 158–8. Russian.
  18. Petrović J, Pešić V, Lauschke VM. Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe. European journal of Human Genetics. 2020; 28 (1): 88–94.
  19. Pedersen RS, Brasch-Andersen C, Sim SC, et al. Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. European journal of clinical pharmacology. 2010; 66: 1199–1205.20.